Over the last decade, prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has become a major focus point in the treatment of advanced prostate cancer (PCa), such as for treatment of patients with (metastasized) castration resistant prostate cancer (CRPC). This evidence concerns the gene FOLH1 and Familial prostate cancer.